BRPI0819453A2 - Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit - Google Patents

Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit

Info

Publication number: BRPI0819453A2
Authority: BR; Brazil
Prior art keywords: kinase activity; compound; treat; composition; karmaceutical
Prior art date: 2007-11-28

Application number

BRPI0819453-0A2A

Other languages

English (en)

Inventor

Nathanael S Gray

Jianming Zhang

Barun Okram

Xianming Deng

Jaewon Chang

Amy Wojciechowski

Original Assignee

Dana Farber Cancer Inst Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-11-28

Filing date

2008-11-28

Publication date

2014-10-07

2008-11-28 Application filed by Dana Farber Cancer Inst Inc filed Critical Dana Farber Cancer Inst Inc

2014-10-07 Publication of BRPI0819453A2 publication Critical patent/BRPI0819453A2/pt

Links

108091000080 Phosphotransferase Proteins 0.000 title 3
102000020233 phosphotransferase Human genes 0.000 title 3
150000001875 compounds Chemical class 0.000 title 2
WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 title 1
206010028980 Neoplasm Diseases 0.000 title 1
201000011510 cancer Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
239000000203 mixture Substances 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Dermatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Plural Heterocyclic Compounds (AREA)
Saccharide Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BRPI0819453-0A2A 2007-11-28 2008-11-28 Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit BRPI0819453A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US446207P	2007-11-28	2007-11-28
PCT/US2008/013219 WO2009073153A2 (en)	2007-11-28	2008-11-28	Small molecule myristate inhibitors of bcr-abl and methods of use

Publications (1)

Publication Number	Publication Date
BRPI0819453A2 true BRPI0819453A2 (pt)	2014-10-07

Family

ID=40718412

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0819453-0A2A BRPI0819453A2 (pt)	2007-11-28	2008-11-28	Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit

Country Status (12)

Country	Link
US (7)	US8921336B2 (pt)
EP (4)	EP3150593B8 (pt)
JP (2)	JP5779778B2 (pt)
KR (1)	KR20100130583A (pt)
CN (3)	CN104327084B (pt)
AU (1)	AU2008331867B2 (pt)
BR (1)	BRPI0819453A2 (pt)
CA (1)	CA2707046A1 (pt)
EA (1)	EA019869B1 (pt)
ES (3)	ES2610190T3 (pt)
MX (3)	MX2010005671A (pt)
WO (1)	WO2009073153A2 (pt)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BRPI0819453A2 (pt) *	2007-11-28	2014-10-07	Dana Farber Cancer Inst Inc	Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit
PT2300013T (pt)	2008-05-21	2017-10-31	Ariad Pharma Inc	Derivados de fósforo como inibidores de cinases
US9273077B2 (en)	2008-05-21	2016-03-01	Ariad Pharmaceuticals, Inc.	Phosphorus derivatives as kinase inhibitors
CN102271515B (zh)	2008-10-31	2014-07-02	健泰科生物技术公司	吡唑并嘧啶jak抑制剂化合物和方法
UA110324C2 (en)	2009-07-02	2015-12-25	Genentech Inc	Jak inhibitory compounds based on pyrazolo pyrimidine
TW201111385A (en) *	2009-08-27	2011-04-01	Biocryst Pharm Inc	Heterocyclic compounds as janus kinase inhibitors
UY33246A (es) *	2010-02-26	2011-09-30	Boehringer Ingelheim Int	Tienopirimidinas que contienen cicloalquilo para composiciones farmacéuticas
EP2539343B1 (en) *	2010-02-26	2015-12-30	Evotec International GmbH	Thienopyrimidines containing a substituted alkyl group for pharmaceutical compositions
UY33241A (es) *	2010-02-26	2011-09-30	Boehringer Ingelheim Int	?Tienopirimidinas que contienen heterocicloalquilo para composiciones farmacéuticas?.
US8927547B2 (en)	2010-05-21	2015-01-06	Noviga Research Ab	Pyrimidine derivatives
MX2013003019A (es)	2010-09-15	2013-05-28	Hoffmann La Roche	Compuestos de azabenzotiazol, composiciones y metodos de uso.
MX2013005445A (es) *	2010-11-19	2013-07-29	Hoffmann La Roche	Pirazolopiridinas y el uso de pirazolopiridinas como inhibidores de tirosina cinasa 2 (tyk2).
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
DK2688883T3 (en)	2011-03-24	2016-09-05	Noviga Res Ab	pyrimidine
US9834518B2 (en)	2011-05-04	2017-12-05	Ariad Pharmaceuticals, Inc.	Compounds for inhibiting cell proliferation in EGFR-driven cancers
EP2548878A1 (en) *	2011-07-21	2013-01-23	Laboratorios Del. Dr. Esteve, S.A.	Pyrazolo[3,4-d]pyrimidine compounds, their preparation and use as sigma ligands
ES2567552T3 (es) *	2012-01-30	2016-04-25	Cephalon, Inc.	Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
US20150166591A1 (en)	2012-05-05	2015-06-18	Ariad Pharmaceuticals, Inc.	Methods and compositions for raf kinase mediated diseases
ES2704744T3 (es)	2012-06-13	2019-03-19	Incyte Holdings Corp	Compuestos tricíclicos sustituidos como inhibidores de FGFR
CN102746308B (zh) *	2012-07-09	2014-12-31	四川大学	别嘌醇衍生物及其制备方法和用途
CN102746306B (zh) *	2012-07-09	2014-11-19	四川国康药业有限公司	别嘌醇类衍生物及其制备方法和用途
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
WO2014152716A1 (en) *	2013-03-15	2014-09-25	President And Fellows Of Harvard College	Substituted heterocyclic compounds for treating or preventing viral infections
US9611283B1 (en)	2013-04-10	2017-04-04	Ariad Pharmaceuticals, Inc.	Methods for inhibiting cell proliferation in ALK-driven cancers
EA035095B1 (ru)	2013-04-19	2020-04-27	Инсайт Холдингс Корпорейшн	Бициклические гетероциклы в качестве ингибиторов fgfr
PE20211782A1 (es)	2014-05-23	2021-09-08	Hoffmann La Roche	Compuestos de 5-cloro-2-difluorometoxifenil pirazolopirimidina, composiciones y metodos de uso de los mismos
US10457691B2 (en)	2014-07-21	2019-10-29	Dana-Farber Cancer Institute, Inc.	Macrocyclic kinase inhibitors and uses thereof
AU2015292818B2 (en)	2014-07-21	2020-01-16	Dana-Farber Cancer Institute, Inc.	Imidazolyl kinase inhibitors and uses thereof
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (en)	2015-02-20	2016-08-25	Incyte Corporation	Bicyclic heterocycles as fgfr4 inhibitors
MX373169B (es)	2015-02-20	2020-04-24	Incyte Holdings Corp	Heterociclos bicíclicos como inhibidores de receptores del factor de crecimiento fibroblástico (fgfr).
WO2016173557A1 (zh) *	2015-04-30	2016-11-03	中国科学院上海药物研究所	一类具有激酶抑制活性的化合物、制备方法和用途
CN105561040A (zh) *	2016-02-24	2016-05-11	梁功	一种治疗偏瘫的中药组合物
CN105777657A (zh) *	2016-03-01	2016-07-20	张宏业	一种治疗偏瘫的药物组合物
US10722484B2 (en)	2016-03-09	2020-07-28	K-Gen, Inc.	Methods of cancer treatment
AU2017291812B2 (en)	2016-07-05	2023-12-14	Dana-Farber Cancer Institute, Inc.	Bicyclic urea kinase inhibitors and uses thereof
WO2018053373A1 (en)	2016-09-16	2018-03-22	The General Hospital Corporation	Uses of satl-inducible kinase (sik) inhibitors for treating osteoporosis
CA3042301A1 (en) *	2016-11-22	2018-05-31	Dana-Farber Cancer Institute, Inc.	Degradation of protein kinases by conjugation of protein kinase inhibitors with e3 ligase ligand and methods of use
BR112019017741A2 (pt)	2017-02-28	2020-04-07	Dana Farber Cancer Inst Inc	usos de pirimidopirimidinonas como inibidores de sik
WO2018215389A1 (en)	2017-05-22	2018-11-29	F. Hoffmann-La Roche Ag	Therapeutic compounds and compositions, and methods of use thereof
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
MA52493A (fr)	2018-05-04	2021-03-10	Incyte Corp	Sels d'un inhibiteur de fgfr
CR20200590A (es)	2018-05-04	2021-04-26	Incyte Corp	Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
CA3103048A1 (en) *	2018-06-21	2019-12-26	Janssen Pharmaceutica Nv	Oga inhibitor compounds
CA3118752A1 (en)	2018-11-09	2020-05-14	Vivace Therapeutics, Inc.	Bicyclic compounds
WO2020185532A1 (en)	2019-03-08	2020-09-17	Incyte Corporation	Methods of treating cancer with an fgfr inhibitor
HUE070525T2 (hu)	2019-04-16	2025-06-28	Vivace Therapeutics Inc	Biciklusos vegyületek
WO2021007269A1 (en)	2019-07-09	2021-01-14	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
WO2021067374A1 (en)	2019-10-01	2021-04-08	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
TWI891666B (zh)	2019-10-14	2025-08-01	美商英塞特公司	作為ｆｇｆｒ抑制劑之雙環雜環
WO2021076728A1 (en)	2019-10-16	2021-04-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
EP4069696A1 (en)	2019-12-04	2022-10-12	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
BR112022010664A2 (pt)	2019-12-04	2022-08-16	Incyte Corp	Derivados de um inibidor de fgfr
WO2021146424A1 (en)	2020-01-15	2021-07-22	Incyte Corporation	Bicyclic heterocycles as fgfr inhibitors
US20240025913A1 (en) *	2020-10-21	2024-01-25	Vivace Therapeutics, Inc.	Tertiary carboxamide compounds
TW202304459A (zh)	2021-04-12	2023-02-01	美商英塞特公司	包含ｆｇｆｒ抑制劑及ｎｅｃｔｉｎ－４靶向劑之組合療法
WO2022261627A1 (en) *	2021-06-07	2022-12-15	The General Hospital Corporation	Inhibitors of ttbk1
EP4352059A1 (en)	2021-06-09	2024-04-17	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors
WO2022261159A1 (en)	2021-06-09	2022-12-15	Incyte Corporation	Tricyclic heterocycles as fgfr inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL112249A (en) *	1994-01-25	2001-11-25	Warner Lambert Co	Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
WO1998012184A1 (en) *	1996-09-19	1998-03-26	Nippon Soda Co., Ltd.	Pyrimidine compounds, process for the preparation thereof, and pest controlling agents
US6413971B1 (en) *	1996-11-27	2002-07-02	Pfizer Inc	Fused bicyclic pyrimidine derivatives
CA2309690A1 (en) *	1997-11-11	1999-05-20	Pfizer Products Inc.	Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
BR9911365A (pt) *	1998-06-19	2001-03-13	Pfizer Prod Inc	Compostos pirrolo[2,3-d]pirimidina
US6258820B1 (en) *	1999-03-19	2001-07-10	Parker Hughes Institute	Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
EP1297194B1 (en)	2000-07-06	2004-10-13	Alcan International Limited	Method of making aluminum foil for fins
AU2002228922A1 (en) *	2000-12-12	2002-06-24	Cytovia, Inc.	Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
CZ294535B6 (cs) *	2001-08-02	2005-01-12	Ústav Experimentální Botaniky Avčr	Heterocyklické sloučeniny na bázi N6-substituovaného adeninu, způsoby jejich přípravy, jejich použití pro přípravu léčiv, kosmetických přípravků a růstových regulátorů, farmaceutické přípravky, kosmetické přípravky a růstové regulátory tyto sloučeniny obsahující
EP1578722A4 (en) *	2001-10-12	2006-09-06	Irm Llc	KINASEINHIBITOR SCAFFOLD AND METHOD FOR THE PRODUCTION THEREOF
CN1627944A (zh) *	2002-01-17	2005-06-15	神经能质公司	取代的喹唑啉－4－基胺类似物作为辣椒辣素调节剂
TW200400034A (en) *	2002-05-20	2004-01-01	Bristol Myers Squibb Co	Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
US7125997B2 (en) *	2002-12-20	2006-10-24	Irm Llc	Differential tumor cytotoxicity compounds and compositions
CN1798734A (zh) *	2003-04-04	2006-07-05	Irm责任有限公司	作为蛋白激酶抑制剂的新化合物和组合物
US20050014753A1 (en) *	2003-04-04	2005-01-20	Irm Llc	Novel compounds and compositions as protein kinase inhibitors
MXPA06001098A (es) *	2003-07-29	2006-04-24	Irm Llc	Compuestos y composiciones utiles como inhibidores de proteina cinasa.
US7338957B2 (en) *	2003-08-28	2008-03-04	Irm Llc	Compounds and compositions as protein kinase inhibitors
GB0326168D0 (en)	2003-11-10	2003-12-17	Arrow Therapeutics Ltd	Chemical compounds
US7820654B2 (en)	2004-09-23	2010-10-26	Dr. Reddy's Laboratories Ltd.	Pyrimidine compounds, process for their preparation and compositions containing them
US20070009977A1 (en) *	2005-01-12	2007-01-11	Boyce James P	Kinase-directed, activity-based probes
WO2006124874A2 (en) *	2005-05-12	2006-11-23	Kalypsys, Inc.	Inhibitors of b-raf kinase
EP1899353A1 (en) *	2005-06-22	2008-03-19	DeveloGen Aktiengesellschaft	Thienopyrimidines for pharmaceutical compositions
WO2008005303A2 (en) *	2006-06-30	2008-01-10	Janssen Pharmaceutica N.V.	Thiazolopyrimidine modulators of trpv1
BRPI0819453A2 (pt) *	2007-11-28	2014-10-07	Dana Farber Cancer Inst Inc	Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit

2008
- 2008-11-28 BR BRPI0819453-0A2A patent/BRPI0819453A2/pt not_active IP Right Cessation
- 2008-11-28 EP EP16197611.3A patent/EP3150593B8/en active Active
- 2008-11-28 KR KR1020107013953A patent/KR20100130583A/ko not_active Ceased
- 2008-11-28 EP EP19170210.9A patent/EP3536687B8/en active Active
- 2008-11-28 WO PCT/US2008/013219 patent/WO2009073153A2/en not_active Ceased
- 2008-11-28 US US12/745,496 patent/US8921336B2/en active Active
- 2008-11-28 MX MX2010005671A patent/MX2010005671A/es active IP Right Grant
- 2008-11-28 ES ES08857261.5T patent/ES2610190T3/es active Active
- 2008-11-28 CN CN201410497692.5A patent/CN104327084B/zh active Active
- 2008-11-28 EP EP21184206.7A patent/EP3912973A3/en active Pending
- 2008-11-28 CN CN201410497500.0A patent/CN104311563B/zh active Active
- 2008-11-28 AU AU2008331867A patent/AU2008331867B2/en not_active Ceased
- 2008-11-28 CA CA2707046A patent/CA2707046A1/en not_active Abandoned
- 2008-11-28 JP JP2010536015A patent/JP5779778B2/ja active Active
- 2008-11-28 EA EA201070595A patent/EA019869B1/ru not_active IP Right Cessation
- 2008-11-28 ES ES16197611T patent/ES2734288T3/es active Active
- 2008-11-28 CN CN200880123462.5A patent/CN101917849B/zh active Active
- 2008-11-28 ES ES19170210T patent/ES2893580T3/es active Active
- 2008-11-28 EP EP08857261.5A patent/EP2222162B1/en active Active
2012
- 2012-03-16 MX MX2012003309A patent/MX2012003309A/es not_active Application Discontinuation
- 2012-03-16 MX MX2012003311A patent/MX2012003311A/es not_active Application Discontinuation
2014
- 2014-10-03 JP JP2014204682A patent/JP5941513B2/ja active Active
- 2014-11-13 US US14/540,919 patent/US9670214B2/en active Active
2017
- 2017-04-28 US US15/582,004 patent/US20170349595A1/en not_active Abandoned
2018
- 2018-10-25 US US16/170,921 patent/US10787455B2/en active Active
2020
- 2020-07-20 US US16/933,095 patent/US11254682B2/en active Active
2022
- 2022-01-12 US US17/574,132 patent/US11932646B2/en active Active
2024
- 2024-01-24 US US18/421,738 patent/US20240158403A1/en active Pending

Also Published As

Publication number	Publication date
CN104327084A (zh)	2015-02-04
US11254682B2 (en)	2022-02-22
WO2009073153A3 (en)	2009-12-30
WO2009073153A2 (en)	2009-06-11
AU2008331867A1 (en)	2009-06-11
JP2015051977A (ja)	2015-03-19
CN104311563A (zh)	2015-01-28
CN104327084B (zh)	2017-06-06
EP3912973A3 (en)	2022-02-16
ES2610190T3 (es)	2017-04-26
US11932646B2 (en)	2024-03-19
EA201070595A1 (ru)	2011-02-28
EA019869B1 (ru)	2014-06-30
EP3536687A1 (en)	2019-09-11
ES2734288T3 (es)	2019-12-05
EP3536687B8 (en)	2021-09-08
US20240158403A1 (en)	2024-05-16
EP2222162A2 (en)	2010-09-01
EP3536687B1 (en)	2021-07-14
KR20100130583A (ko)	2010-12-13
ES2893580T3 (es)	2022-02-09
EP2222162A4 (en)	2012-01-18
US20190084990A1 (en)	2019-03-21
MX2012003309A (es)	2012-11-20
US9670214B2 (en)	2017-06-06
CN101917849A (zh)	2010-12-15
CN101917849B (zh)	2014-11-05
EP3150593B8 (en)	2019-08-21
EP3912973A2 (en)	2021-11-24
AU2008331867B2 (en)	2014-05-22
US20150094275A1 (en)	2015-04-02
CA2707046A1 (en)	2009-06-11
JP5941513B2 (ja)	2016-06-29
JP5779778B2 (ja)	2015-09-16
US20170349595A1 (en)	2017-12-07
US20200347068A1 (en)	2020-11-05
EP3150593B1 (en)	2019-04-24
JP2011504927A (ja)	2011-02-17
EP3150593A1 (en)	2017-04-05
US20220135573A1 (en)	2022-05-05
MX2010005671A (es)	2010-06-25
CN104311563B (zh)	2016-12-07
MX2012003311A (es)	2013-05-08
US10787455B2 (en)	2020-09-29
US8921336B2 (en)	2014-12-30
US20110312908A1 (en)	2011-12-22
EP2222162B1 (en)	2016-11-16

Legal Events

Date	Code	Title	Description
2015-06-09	B25D	Requested change of name of applicant approved	Owner name: DANA-FARBER CANCER INSTITUTE, INC. (US)
2016-09-27	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-01-17	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.

Publication	Publication Date	Title
BRPI0819453A2 (pt)	2014-10-07	Composto, métodos para tratar um distúrbio relacionado com atividade de cinase, para tratar câncer em um paciente, para inibir a atividade de cinase e para identificar um composto que modula a atividade de cinase de bcr-abl, composição farmacêutica, e, kit
BRPI0813311A2 (pt)	2014-12-23	Composto, métodos para modulara a atividade de uma proteína quinase e para tratar câncer em um indivíduo, e, composição farmacêutica.
BRPI0821209A2 (pt)	2019-09-24	composto, composição farmacêutica, métodos de tratar câncer, para reduzir o tamanho de tumor, para tratar distúrbios, e para reduzir metástase em um tumor.
CL2008002381A1 (es)	2009-02-13	Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer.
BRPI0917711A2 (pt)	2017-06-20	método para avaliar o estado renal em um paciente, e, uso de um ou mais marcadores de lesão renal
BR112013033940A2 (pt)	2017-02-14	terapia combinada compreendendo um inibidor de cdk4/6 e um inibidor de pi3k para uso no tratamento de câncer
BRPI1007046A2 (pt)	2015-07-21	Inibidores axl para uso em terapia de combinação para evitar, tratar ou controlar o câncer metastático.
BRPI0818287A2 (pt)	2015-11-03	células dendríticas manipuladas e usos para o tratamento do câncer.
CL2008002319A1 (es)	2009-01-02	Compuestos derivados de pirrolopirimidina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BR112015003332A2 (pt)	2017-09-26	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BR112013011480A2 (pt)	2016-08-09	método de tratamento de câncer, método de aumento da eficácia terapêutica de uma droga anticâncer, pmo1183 ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo e kit para uso no tratamento de câncer
BRPI0811059A2 (pt)	2017-05-09	combinação, composição farmacêutica, método para tratar câncer em um animal de sangue quente, e, uso de uma combinação
BR112015003398A2 (pt)	2018-04-24	composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
BRPI0811589A2 (pt)	2014-10-29	Composição farmacêutica e método para tratar câncer
BRPI0818244A2 (pt)	2015-06-16	Composto, composição farmacêutica, uso de um composto, e, método para tratamento de um distúrbio ou doença
BR112012018947A2 (pt)	2017-06-27	composição farmacêutica para tratamento e\ou prevenção do cancêr
BRPI0816097A2 (pt)	2016-11-01	composição farmacêutica, método para tratar eritema em um paciente com rosácea, e, uso de uma composição.
CL2008001323A1 (es)	2009-05-29	Compuestos derivados de triazolil aminopiridina; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar cancer.
BRPI1011505A2 (pt)	2016-03-22	formas de pró-drogas de inibidores de quinase e sua aplicação em terapia
BRPI0813456A2 (pt)	2014-12-23	Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença
BRPI0915105A2 (pt)	2019-09-24	composto de 2,4'-biripidinila como inibidores da proteína cinase d úteis para o tratamento de ia insuficiência cardíaca e cancer
PL2695528T3 (pl)	2021-12-27	Kompozycja żywieniowa do usprawniania funkcji mięśni i codziennej aktywności
BR112013014522A2 (pt)	2017-09-26	anticorpo anti-cd20 afucosilado e seu uso, composição e método para tratamento de um paciente que sofre de câncer
ZA200907245B (en)	2010-07-28	Phthalazinone derivatives and their use as medicament to treat cancer
BRPI0922452A2 (pt)	2015-12-15	composto, composição farmacêutica, uso em um composto, e método para prevenir, tratar ou melhorar doenças ou condições dérmicas, ou distúrbios de ferimento cutâneo agudos ou crônicos.